CPX-351: Phase II data

Data from the open-label, U.S. and Canadian Phase II CLTR0308-204 trial in 126 patients ages 60-75 with newly diagnosed AML showed that CPX-351 met the primary endpoint of a significantly higher complete remission rate vs. standard cytarabine and daunorubicin. Celator also said that CPX-351 reduced 30- and 60-day mortality rates vs. standard cytarabine and daunorubicin. Patients received 100 µg/m 2 of CPX-351 given as a 90-minute infusion on days 1, 3 and 5 or 100 mg/m 2/day cytarabine as a continuous infusion for 7 days plus 60 mg/m 2/day IV daunorubicin for 3 days. ...